Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Added to Russell 3000 Index

NEW YORK (GenomeWeb News) - Alnylam Pharmaceuticals was added to the Russell 3000 and Russell 2000 after the markets closed on June 30, the company said today.
Alynlam said its inclusion in these indexes reflects an interest "in the potential of RNAi for therapeutic applications, and the promise of this technology," said John Maraganore, president and CEO of Alnylam Pharmaceuticals.
The Russell Indeces include only common stocks belonging to US corporations. The Russell 3000 measures the performance based on total market capitalization. Alnylam's market cap is currently $471 million.
Also listed on this index are: Applied Biosystems, Affymetrix, Agilent, Beckman Coulter, Becton Dickinson, Bio-Rad, Bruker BioSciences, Cepheid, DeCode, Fisher Scientific, General Electric, Illumina, Invitrogen, Luminex, Molecular Devices, PerkinElmer, Serologicals, Sigma-Aldrich, Solexa (which was added earlier this week), Thermo Electron, and Waters.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.